6OGE image
Deposition Date 2019-04-02
Release Date 2019-05-15
Last Version Date 2024-11-20
Entry Detail
PDB ID:
6OGE
Title:
Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
4.36 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Receptor tyrosine-protein kinase erbB-2
Gene (Uniprot):ERBB2
Chain IDs:A
Chain Length:622
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Pertuzumab FAB LIGHT CHAIN
Gene (Uniprot):IGKC
Chain IDs:B
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Pertuzumab FAB HEAVY CHAIN
Chain IDs:C
Chain Length:222
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Trastuzumab FAB LIGHT CHAIN
Gene (Uniprot):IGKC
Chain IDs:D
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Trastuzumab FAB HEAVY CHAIN
Gene (Uniprot):IGH@
Chain IDs:E
Chain Length:220
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
Plos One 14 e0216095 e0216095 (2019)
PMID: 31042744 DOI: 10.1371/journal.pone.0216095

Abstact

Trastuzumab and pertuzumab are monoclonal antibodies that bind to distinct subdomains of the extracellular domain of human epidermal growth factor receptor 2 (HER2). Adding these monoclonal antibodies to the treatment regimen of HER2-positive breast cancer has changed the paradigm for treatment in that form of cancer. Synergistic activity has been observed with the combination of these two antibodies leading to hypotheses regarding the mechanism(s) and to the development of bispecific antibodies to maximize the clinical effect further. Although the individual crystal structures of HER2-trastuzumab and HER2-pertuzumab revealed the distinct binding sites and provided the structural basis for their anti-tumor activities, detailed structural information on the HER2-trastuzumab-pertuzumab complex has been elusive. Here we present the cryo-EM structure of HER2-trastuzumab-pertuzumab at 4.36 Å resolution. Comparison with the binary complexes reveals no cooperative interaction between trastuzumab and pertuzumab, and provides key insights into the design of novel, high-avidity bispecific molecules with potentially greater clinical efficacy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures